Page last updated: 2024-11-06

phorbol 12,13-dibutyrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phorbol 12,13-Dibutyrate: A phorbol ester found in CROTON OIL which, in addition to being a potent skin tumor promoter, is also an effective activator of calcium-activated, phospholipid-dependent protein kinase (protein kinase C). Due to its activation of this enzyme, phorbol 12,13-dibutyrate profoundly affects many different biological systems. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CrotongenusA plant genus of the family EUPHORBIACEAE. The common name of dragon's blood is also used for DRACAENA and Daemonorops (ARECACEAE). Croton tiglium is the source of CROTON OIL.[MeSH]EuphorbiaceaeThe spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH]

Cross-References

ID SourceID
PubMed CID37783
CHEBI ID17598
SCHEMBL ID162855
MeSH IDM0023428

Synonyms (43)

Synonym
BRD-K81365681-001-01-8
CHEBI:17598 ,
(1ar,1bs,4ar,7as,7bs,8r,9r,9as)-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-9ah-cyclopropa[3,4]benzo[1,2-e]azulene-9,9a-diyl dibutanoate
butanoic acid, 1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa(3,4)benz(1,2-e)azulene-9,9a-diyl ester, (1ar-(1a-alpha,1b-beta,4a-beta,7a-alpha,7b-alpha,8-alpha,9-beta,9a-alpha))-
nsc 622507
HSCI1_000181
phorbol dibutyrate
4-.beta.-phorbol 12,13-dibutyrate
[butanoyloxy-dihydroxy-(hydroxymethyl)-tetramethyl-oxo-[?]yl] butanoate
butanoic acid, (1ar,1bs,4ar,7as,7bs,8r,9r,9as)-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa[3,4]benz[1,2-e]azulene-9,9a-diyl ester
phorbol 12,13-dibutyrate
pdbu
C03634
37558-16-0
phorbol 12,13-dibutanoate
phorbol 12,13-dibutyrate, >=98% (tlc), powder
NCGC00163607-01
butanoic acid, 1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa(3,4)benz(1,2-e)azulene-9,9a-diyl ester, (1ar-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))-
[3h]-phorbol 12,13-dibutyrate
unii-67mx82cl58
butanoic acid, (1ar,1bs,4ar,7as,7bs,8r,9r,9as)-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa(3,4)benz(1,2-e)azulene-9,9a-diyl ester
67mx82cl58 ,
butanoic acid, diester with 1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-4a,7b,9,9a-tetrahydro-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5h-cyclopropya(3,4)benz(1,2-e)azulen-5-one, (1ar-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))-
butanoic acid, (1ar,1bs,4ar,7bs,8r,9r,9as)-1,1a,1b,4,4a,5,7a,7b,8,9-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-9ah-cyclopropa(3,4)benz(1,2-e)azulene-9,9a-diyl ester
61557-88-8
CCG-208247
SCHEMBL162855
phorbol12,13-dibutyrate
(1ar,1bs,4ar,7as,7bs,8r,9r,9as)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1h-cyclopropa[3,4]benz[1,2-e]azulen-9,9a-diyl butanoic acid ester
AKOS024458006
mfcd00036783
SR-05000002331-2
SR-05000002331-3
sr-05000002331
BQJRUJTZSGYBEZ-YVQNUNKESA-N
phorbol 12,13-dibutyrate >99%
Q7187368
[(1s,2s,6r,10s,11r,13s,14r,15r)-13-butanoyloxy-1,6-dihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-5-oxo-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] butanoate
CS-0014826
HY-18985
pkc activator ii
MS-29372
DTXSID50958628

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"1 to 100 microM), involved a temperature-dependent process, could not be mimicked by addition of hematopoietic growth factors, and was not related to neutralization of toxic or inhibitory substances in high-density medium."( In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Boise, L; Grant, S; Howe, C; McCrady, C; Pettit, GR; Turner, A; Westin, E, 1991
)
0.28
" The concentration of toxic thresholds varied from cell type to cell type."( Psychosine cytotoxicity in rat neural cell cultures and protection by phorbol ester and dimethyl sulfoxide.
Eto, Y; Ida, H; Kim, SU; Sugama, S, 1990
)
0.28
" Previously we showed that in primary thyroid follicular cells, expression of mutant p21ras conferred a striking sensitivity to the toxic effects of phorbol esters."( Toxicity of phorbol esters for human epithelial cells expressing a mutant ras oncogene.
Bond, J; Dawson, T; Eccles, N; Wynford-Thomas, D, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" It has been proposed that the lipid phosphate phosphatases exhibit ecto activity that may function to limit bioavailability of these lipid agonists at their receptors."( G-protein-coupled receptor stimulation of the p42/p44 mitogen-activated protein kinase pathway is attenuated by lipid phosphate phosphatases 1, 1a, and 2 in human embryonic kidney 293 cells.
Ahmed, IS; Alderton, F; Darroch, P; McKie, A; Pyne, N; Pyne, S; Sambi, B, 2001
)
0.31

Dosage Studied

A similar dose-response effect was seen with sapintoxin D (SAP D), the stage 2 promoting analogue of 12-O-tetradecanoylphorbol-13-acetate and the complete promoter phorbol 12,13-dibutyrate (PDB) Ca2+ ionophore A23187 caused release of vasoactive intestinal polypeptide dose dependently.

ExcerptRelevanceReference
" Increase in extracellular K+ concentration (10, 15 mM) shifted the dose-response relationship for the ET-1-induced contraction to the left."( A pertussis toxin-sensitive mechanism of endothelin action in porcine coronary artery smooth muscle.
Goto, K; Kasuya, Y; Masaki, T; Takuwa, Y; Yanagisawa, M, 1992
)
0.28
" First, in dose-response experiments, it was shown that 10 times the concentration of IL-4 was required for CD23 than for sIgM expression."( Independent regulation of interleukin 4 (IL-4)-induced expression of human B cell surface CD23 and IgM: functional evidence for two IL-4 receptors.
Callard, RE; Rigley, KP; Thurstan, SM, 1991
)
0.28
" A23187 caused release of vasoactive intestinal polypeptide dose dependently and phorbol 12,13-dibutyrate (100 nM) markedly shifted the dose-response curve of A23187 to the left."( Enhancement of A23187-induced release of enteric vasoactive intestinal polypeptide by phorbol 12,13-dibutyrate.
Belai, A; Burnstock, G; Dale, MM, 1990
)
0.73
" A similar dose-response effect was seen with sapintoxin D (SAP D), the stage 2 promoting analogue of 12-O-tetradecanoylphorbol-13-acetate and the complete promoter phorbol 12,13-dibutyrate (PDB)."( Both tumour-promoting and non-promoting phorbol esters inhibit [125I]EGF binding and stimulate the phosphorylation of an 80 kd protein kinase C substrate protein in intact quiescent swiss 3T3 cells.
Brooks, G; Brooks, SF, 1990
)
0.47
" Dose-response studies revealed that PGF2 alpha increased the potency of insulin in granulosa cells (EC50 for insulin-stimulation of oxytocin release reduced from 141 to 13 nmol/l by 1 mumol PGF2 alpha/l), but not in luteal cells."( Chronic regulation of ovarian oxytocin and progesterone release by prostaglandins: opposite effects in bovine granulosa and early luteal cells.
McArdle, CA, 1990
)
0.28
" This enhancement is particularly striking at decreased effector:target ratios (as low as one effector per five targets) and is also demonstrated by a shift to lower concentrations of the phorbol diester dose-response curve."( Enhancement of phorbol diester-induced HL-60-mediated cytotoxicity by retinoic acid, dimethyl sulfoxide, and 5-azacytidine.
Hall, RE; Leftwich, JA, 1986
)
0.27
" The dose-response curve of the potassium response followed classical Michaelis-Menten kinetics."( Further characterization of the slow muscarinic responses in Xenopus oocytes.
Cohen, S; Dascal, N, 1987
)
0.27
" At 6 h post DE, there were no differences between the dose-response curves obtained from aortic rings with or without endothelium."( Effect of endothelium removal on stimulatory and inhibitory modulation of rat aortic prostacyclin synthesis.
Dandona, P; Jeremy, JY, 1989
)
0.28
" Moreover, PDBu, which causes attenuation of the maximal response to vasoactive intestinal polypeptide (VIP), also induced a small right shift in the dose-response curve for VIP-induced cyclic AMP accumulation."( Regulation of GH3 pituitary tumour-cell adenylate cyclase activity by activators of protein kinase C.
Brown, BL; Dobson, PR; Quilliam, LA, 1989
)
0.28
" Dose-response studies indicate that the desensitization was associated with a major reduction in the maximal extent of agonist-induced responses."( Homologous desensitization of muscarinic cholinergic, histaminergic, adrenergic, and serotonergic receptors coupled to phospholipase C in cerebellar granule cells.
Chuang, DM; Dillon-Carter, O, 1989
)
0.28
" The NaF-PGI2 dose-response curve was moved to the left by the presence of adrenaline, phorbol 12,13-dibutyrate (PDBU) and the Ca2+ ionophore A23187 in the incubation media."( Fluoride stimulates in vitro vascular prostacyclin synthesis: interrelationship of G proteins and protein kinase C.
Dandona, P; Jeremy, JY, 1988
)
0.5
" Dose-response curves of phorbol-12,13-dibutyrate-induced muscle tension and -stimulated kinase activity and receptor binding indicate that these responses are mediated by the same system."( Schistosoma mansoni: evidence for protein kinase-C-like modulation of muscle activity.
Bennett, JL; Blair, KL; Pax, RA, 1988
)
0.27
" When HT-39 cells were grown in medium containing different calcium levels and dosed with 10 nM 1,25-(OH)2D3, we found that the inhibitory action of 1,25-(OH)2D3 was modified."( Calcium antagonizes 1,25-dihydroxyvitamin D3 inhibition of breast cancer cell proliferation.
Arnold, AJ; Simpson, RU, 1986
)
0.27
" Dose-response curves for ET-1 relaxation were shifted to the left."( Two receptor subtypes are involved in the contractile component of the guinea pig ileum responses to endothelins.
Ihara, M; Miasiro, N; Paiva, AC; Yano, M, 1993
)
0.29
" This inhibition reflects the ability of GnRH to shift the CNP dose-response curve rightward (increasing the EC50 for CNP action approximately 10-fold both with and without 3-isobutyl-1-methylxanthine)."( Cyclic guanosine monophosphate production in the pituitary: stimulation by C-type natriuretic peptide and inhibition by gonadotropin-releasing hormone in alpha T3-1 cells.
Käppler, K; McArdle, CA; Poch, A, 1993
)
0.29
" The dose-response curve of adenylate cyclase to the GTP analogue, GppNHp, was modified by 5HT, which promotes a significantly higher maximal response without altering the potency of GppNHp."( Heterologous sensitization of adenylate cyclase activity by serotonin in the rat cerebral cortex.
Brunello, N; Perez, J; Racagni, G; Rovescalli, AC; Steardo, L; Vitali, S, 1993
)
0.29
" EC50s of the dose-response curves for adrenaline, AII and PDBU were also markedly increased in aortae from DM rats compared to controls."( Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat.
Jeremy, JY; Mikhailidis, DP; Thompson, CS, 1993
)
0.29
" The PKC-specific inhibitor GF 109203X (bisindolylmaleimide I) reduced MARCKS phosphorylation in intact cells at a similar dose-response as enzymatic activity of recombinant isoenzymes cPKC-alpha, nPKC-epsilon, and nPKC-theta in vitro."( Conventional PKC-alpha, novel PKC-epsilon and PKC-theta, but not atypical PKC-lambda are MARCKS kinases in intact NIH 3T3 fibroblasts.
Baier, G; Bauer, B; Fresser, F; Giselbrecht, S; Grunicke, HH; Gschwendt, M; Hellbert, K; Uberall, F, 1997
)
0.3
" The dose-response curves obtained with different transmitters all shifted downward after the activation of PKC, but the ED50 of each transmitter remained unchanged."( Functional uncoupling between the receptor and G-protein as the result of PKC activation, observed in Aplysia neurons.
Fujita, R; Kawasaki, S; Kimura, S; Matsumoto, M; Sasaki, K; Sato, M; Takashima, K, 1997
)
0.3
" PDBu did not affect the dose-response relation of NE in Mn-loaded preparations."( Effects of phorbol-12,13-dibutyrate and protein kinase C inhibitors on Mn(2+)-dependent norepinephrine-induced contractions involving increase in Mn2+ sensitivity in Ca(2+)-depleted vas deferens of the guinea pig.
Gomi, Y; Tsunobuchi-Ushijima, H, 1997
)
0.3
" The time profile and the dose-response relationship paralleled with those of cytosolic free Ca2+ concentration ([Ca2+]i)."( Carbachol-induced [Ca2+]i increase, but not activation of protein kinase C, stimulates exocytosis in rat parotid acini.
Murakami, M; Segawa, A; Yoshimura, K, 2000
)
0.31
"In vitro-perfused SMA vascular beds were tested for the cumulative dose-response to octreotide at baseline conditions and after preconstriction with different vasoconstrictors (alpha1-agonist methoxamine, endothelin [ET-1], phorbol ester [PdBu], and potassium chloride [KCl])."( Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats.
Groszmann, RJ; Tsai, MH; Wiest, R, 2001
)
0.31
" Phorbol dibutyrate (PDB), an activator of protein kinase C, stimulated basal phospholipid methylation and also shifted the dose-response curve for dopamine-stimulated phospholipid methylation to the right by more than an order of magnitude."( Protein kinase C regulates dopamine D4 receptor-mediated phospholipid methylation.
Deth, RC; Sharma, A; Waly, M, 2001
)
0.31
"), a selective protein kinase C inhibitor, significantly inhibited intrathecal fenvalerate-induced nociceptive behavior with a rightward shift of the dose-response curve for fenvalerate-induced nociceptive behavior to the level those observed in non-diabetic mice."( Modification of the fenvalerate-induced nociceptive response in mice by diabetes.
Iguchi, E; Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2002
)
0.31
" Dose-response and time course studies revealed that mu-calpain was more sensitive to PDBu than m-calpain and the temporal course of the mu-calpain change coincides better with that of APPs release."( Mu-calpain is functionally required for alpha-processing of Alzheimer's beta-amyloid precursor protein.
Chen, M; Fernandez, HL, 2005
)
0.33
" In NPUA sheep, PDBu produced a concentration-dependent potentiation of phenylephrine-induced contractions and shifted the dose-response curve to the left."( Regulation of alpha1-adrenoceptor-mediated contractions of uterine arteries by PKC: effect of pregnancy.
Longo, LD; Xiao, D; Zhang, H; Zhang, L, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
phorbol esterEsters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.
butyrate esterAny carboxylic ester where the carboxylic acid component is butyric acid.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.01260.003245.467312,589.2998AID2517
ATAD5 protein, partialHomo sapiens (human)Potency0.15140.004110.890331.5287AID624252; AID686934; AID720565
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency19.95260.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein kinase C alpha typeBos taurus (cattle)Ki0.00020.00020.01270.0330AID155873
Protein kinase C gamma typeHomo sapiens (human)Ki0.00220.00120.42536.0000AID164030; AID164039
Protein kinase C beta typeHomo sapiens (human)Ki0.00190.00040.69246.0000AID163364; AID163372
Protein kinase C alpha typeHomo sapiens (human)Ki0.00490.00021.09456.9600AID163173; AID163182; AID164151; AID164964
Protein kinase C eta typeHomo sapiens (human)Ki0.00560.00101.16496.0000AID163871; AID163875
Protein kinase C delta typeMus musculus (house mouse)Ki0.02750.00010.52767.0800AID155881; AID155882; AID155883; AID155884; AID155885; AID155886; AID155887; AID155888; AID292150; AID292151; AID292152
Protein kinase C epsilon typeHomo sapiens (human)Ki0.00810.00040.97976.0000AID163841; AID163849
Protein kinase C theta typeHomo sapiens (human)Ki0.00150.00150.65036.0000AID164185
Protein kinase C delta typeHomo sapiens (human)Ki0.04040.00030.94896.9600AID163532; AID163680; AID164819; AID164820; AID164823; AID164824
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein kinase C gamma typeHomo sapiens (human)Kd0.01140.00120.00140.0015AID164028; AID164029; AID164034; AID164035; AID164040; AID164042; AID517264; AID608024
Protein kinase C beta typeHomo sapiens (human)Kd0.00130.00132.708126.3240AID163363; AID163367; AID163368; AID163373; AID163375; AID517263; AID608023
Proto-oncogene vavHomo sapiens (human)Kd0.00100.00100.00100.0010AID1138941
Protein kinase C alpha typeHomo sapiens (human)Kd0.00690.00031.792221.3520AID1189623; AID1189628; AID163021; AID163172; AID163177; AID163178; AID163183; AID163185; AID517262; AID608022
Protein kinase C eta typeHomo sapiens (human)Kd0.00160.00040.28811.8000AID163870; AID163873; AID164048; AID164168; AID164170; AID517268; AID608027
Protein kinase C delta typeMus musculus (house mouse)Kd0.12840.00020.12840.3830AID1138943; AID292153; AID292154
Protein kinase C epsilon typeHomo sapiens (human)Kd0.00190.00020.58498.1000AID1189624; AID1189629; AID163840; AID163844; AID163845; AID163850; AID163852; AID517267; AID608026
Protein kinase C theta typeHomo sapiens (human)Kd0.06760.00071.61407.2000AID164181; AID164184; AID164188; AID164191; AID164367; AID517269
Protein kinase C delta typeHomo sapiens (human)Kd0.04320.00021.12619.2060AID1138942; AID163530; AID163531; AID163675; AID163676; AID163681; AID163683; AID517265; AID517266; AID608025
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Kd0.00200.00200.20160.6000AID292154
Transient receptor potential cation channel subfamily V member 4 Mus musculus (house mouse)EC50 (µMol)22.47000.15001.38006.3000AID353524
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein kinase C alpha typeHomo sapiens (human)ED500.02000.02000.02000.0200AID164150
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (183)

Processvia Protein(s)Taxonomy
angiogenesisProtein kinase C alpha typeBos taurus (cattle)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeBos taurus (cattle)
protein phosphorylationProtein kinase C alpha typeBos taurus (cattle)
apoptotic processProtein kinase C alpha typeBos taurus (cattle)
cell adhesionProtein kinase C alpha typeBos taurus (cattle)
positive regulation of endothelial cell migrationProtein kinase C alpha typeBos taurus (cattle)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeBos taurus (cattle)
positive regulation of cell migrationProtein kinase C alpha typeBos taurus (cattle)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeBos taurus (cattle)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeBos taurus (cattle)
positive regulation of macrophage differentiationProtein kinase C alpha typeBos taurus (cattle)
positive regulation of angiogenesisProtein kinase C alpha typeBos taurus (cattle)
positive regulation of cell adhesionProtein kinase C alpha typeBos taurus (cattle)
positive regulation of mitotic cell cycleProtein kinase C alpha typeBos taurus (cattle)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeBos taurus (cattle)
regulation of platelet aggregationProtein kinase C alpha typeBos taurus (cattle)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeBos taurus (cattle)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeBos taurus (cattle)
protein phosphorylationProtein kinase C gamma typeHomo sapiens (human)
chemical synaptic transmissionProtein kinase C gamma typeHomo sapiens (human)
learning or memoryProtein kinase C gamma typeHomo sapiens (human)
chemosensory behaviorProtein kinase C gamma typeHomo sapiens (human)
response to toxic substanceProtein kinase C gamma typeHomo sapiens (human)
phosphorylationProtein kinase C gamma typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C gamma typeHomo sapiens (human)
regulation of response to foodProtein kinase C gamma typeHomo sapiens (human)
positive regulation of mismatch repairProtein kinase C gamma typeHomo sapiens (human)
negative regulation of protein catabolic processProtein kinase C gamma typeHomo sapiens (human)
regulation of circadian rhythmProtein kinase C gamma typeHomo sapiens (human)
response to morphineProtein kinase C gamma typeHomo sapiens (human)
negative regulation of neuron apoptotic processProtein kinase C gamma typeHomo sapiens (human)
response to painProtein kinase C gamma typeHomo sapiens (human)
rhythmic processProtein kinase C gamma typeHomo sapiens (human)
regulation of phagocytosisProtein kinase C gamma typeHomo sapiens (human)
long-term synaptic potentiationProtein kinase C gamma typeHomo sapiens (human)
innervationProtein kinase C gamma typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C gamma typeHomo sapiens (human)
negative regulation of proteasomal protein catabolic processProtein kinase C gamma typeHomo sapiens (human)
response to psychosocial stressProtein kinase C gamma typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C gamma typeHomo sapiens (human)
intracellular signal transductionProtein kinase C gamma typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C gamma typeHomo sapiens (human)
adaptive immune responseProtein kinase C beta typeHomo sapiens (human)
chromatin remodelingProtein kinase C beta typeHomo sapiens (human)
regulation of transcription by RNA polymerase IIProtein kinase C beta typeHomo sapiens (human)
protein phosphorylationProtein kinase C beta typeHomo sapiens (human)
calcium ion transportProtein kinase C beta typeHomo sapiens (human)
intracellular calcium ion homeostasisProtein kinase C beta typeHomo sapiens (human)
apoptotic processProtein kinase C beta typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C beta typeHomo sapiens (human)
signal transductionProtein kinase C beta typeHomo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
response to xenobiotic stimulusProtein kinase C beta typeHomo sapiens (human)
response to glucoseProtein kinase C beta typeHomo sapiens (human)
regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
negative regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
regulation of dopamine secretionProtein kinase C beta typeHomo sapiens (human)
dibenzo-p-dioxin metabolic processProtein kinase C beta typeHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C beta typeHomo sapiens (human)
response to vitamin DProtein kinase C beta typeHomo sapiens (human)
regulation of growthProtein kinase C beta typeHomo sapiens (human)
B cell activationProtein kinase C beta typeHomo sapiens (human)
positive regulation of odontogenesis of dentin-containing toothProtein kinase C beta typeHomo sapiens (human)
lipoprotein transportProtein kinase C beta typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C beta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C beta typeHomo sapiens (human)
response to ethanolProtein kinase C beta typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C beta typeHomo sapiens (human)
positive regulation of DNA-templated transcriptionProtein kinase C beta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
cellular response to carbohydrate stimulusProtein kinase C beta typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C beta typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C beta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C beta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C beta typeHomo sapiens (human)
regulation of cell sizeProto-oncogene vavHomo sapiens (human)
G protein-coupled receptor signaling pathwayProto-oncogene vavHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene vavHomo sapiens (human)
regulation of cell sizeProto-oncogene vavHomo sapiens (human)
platelet activationProto-oncogene vavHomo sapiens (human)
T cell differentiationProto-oncogene vavHomo sapiens (human)
neutrophil chemotaxisProto-oncogene vavHomo sapiens (human)
T cell costimulationProto-oncogene vavHomo sapiens (human)
intracellular signal transductionProto-oncogene vavHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProto-oncogene vavHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene vavHomo sapiens (human)
natural killer cell mediated cytotoxicityProto-oncogene vavHomo sapiens (human)
regulation of GTPase activityProto-oncogene vavHomo sapiens (human)
positive regulation of natural killer cell mediated cytotoxicityProto-oncogene vavHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene vavHomo sapiens (human)
regulation of small GTPase mediated signal transductionProto-oncogene vavHomo sapiens (human)
cellular response to xenobiotic stimulusProto-oncogene vavHomo sapiens (human)
reactive oxygen species metabolic processProto-oncogene vavHomo sapiens (human)
cell migrationProto-oncogene vavHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C eta typeHomo sapiens (human)
signal transductionProtein kinase C eta typeHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationProtein kinase C eta typeHomo sapiens (human)
cell differentiationProtein kinase C eta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C eta typeHomo sapiens (human)
positive regulation of keratinocyte differentiationProtein kinase C eta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C eta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C eta typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C eta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C eta typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C eta typeHomo sapiens (human)
regulation of bicellular tight junction assemblyProtein kinase C eta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C eta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C eta typeHomo sapiens (human)
MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
macrophage activation involved in immune responseProtein kinase C epsilon typeHomo sapiens (human)
protein phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
apoptotic processProtein kinase C epsilon typeHomo sapiens (human)
signal transductionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of epithelial cell migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of fibroblast migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of actin filament polymerizationProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C epsilon typeHomo sapiens (human)
cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cytokinesisProtein kinase C epsilon typeHomo sapiens (human)
locomotory exploration behaviorProtein kinase C epsilon typeHomo sapiens (human)
TRAM-dependent toll-like receptor 4 signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C epsilon typeHomo sapiens (human)
response to morphineProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of lipid catabolic processProtein kinase C epsilon typeHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein kinase C epsilon typeHomo sapiens (human)
cell divisionProtein kinase C epsilon typeHomo sapiens (human)
establishment of localization in cellProtein kinase C epsilon typeHomo sapiens (human)
synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusProtein kinase C epsilon typeHomo sapiens (human)
mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
cellular response to ethanolProtein kinase C epsilon typeHomo sapiens (human)
cellular response to prostaglandin E stimulusProtein kinase C epsilon typeHomo sapiens (human)
cellular response to hypoxiaProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of wound healingProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cellular glucuronidationProtein kinase C epsilon typeHomo sapiens (human)
intracellular signal transductionProtein kinase C epsilon typeHomo sapiens (human)
regulation of cell growthProtein kinase C theta typeHomo sapiens (human)
regulation of DNA-templated transcriptionProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C theta typeHomo sapiens (human)
membrane protein ectodomain proteolysisProtein kinase C theta typeHomo sapiens (human)
inflammatory responseProtein kinase C theta typeHomo sapiens (human)
axon guidanceProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-17 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-2 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C theta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C theta typeHomo sapiens (human)
CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
positive regulation of T cell activationProtein kinase C theta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomerase activityProtein kinase C theta typeHomo sapiens (human)
cell chemotaxisProtein kinase C theta typeHomo sapiens (human)
negative regulation of T cell apoptotic processProtein kinase C theta typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere cappingProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 17 type immune responseProtein kinase C theta typeHomo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 2 cell activationProtein kinase C theta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (35)

Processvia Protein(s)Taxonomy
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeBos taurus (cattle)
protein bindingProtein kinase C alpha typeBos taurus (cattle)
ATP bindingProtein kinase C alpha typeBos taurus (cattle)
zinc ion bindingProtein kinase C alpha typeBos taurus (cattle)
PDZ domain bindingProtein kinase C alpha typeBos taurus (cattle)
scaffold protein bindingProtein kinase C alpha typeBos taurus (cattle)
protein serine kinase activityProtein kinase C alpha typeBos taurus (cattle)
protein kinase activityProtein kinase C gamma typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C gamma typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C gamma typeHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityProtein kinase C gamma typeHomo sapiens (human)
protein bindingProtein kinase C gamma typeHomo sapiens (human)
ATP bindingProtein kinase C gamma typeHomo sapiens (human)
zinc ion bindingProtein kinase C gamma typeHomo sapiens (human)
protein serine kinase activityProtein kinase C gamma typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C gamma typeHomo sapiens (human)
chromatin bindingProtein kinase C beta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
protein kinase C bindingProtein kinase C beta typeHomo sapiens (human)
calcium channel regulator activityProtein kinase C beta typeHomo sapiens (human)
protein bindingProtein kinase C beta typeHomo sapiens (human)
ATP bindingProtein kinase C beta typeHomo sapiens (human)
zinc ion bindingProtein kinase C beta typeHomo sapiens (human)
nuclear receptor coactivator activityProtein kinase C beta typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C beta typeHomo sapiens (human)
histone bindingProtein kinase C beta typeHomo sapiens (human)
nuclear androgen receptor bindingProtein kinase C beta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C beta typeHomo sapiens (human)
phosphotyrosine residue bindingProto-oncogene vavHomo sapiens (human)
guanyl-nucleotide exchange factor activityProto-oncogene vavHomo sapiens (human)
protein bindingProto-oncogene vavHomo sapiens (human)
metal ion bindingProto-oncogene vavHomo sapiens (human)
phosphorylation-dependent protein bindingProto-oncogene vavHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
protein kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein bindingProtein kinase C eta typeHomo sapiens (human)
ATP bindingProtein kinase C eta typeHomo sapiens (human)
enzyme bindingProtein kinase C eta typeHomo sapiens (human)
small GTPase bindingProtein kinase C eta typeHomo sapiens (human)
metal ion bindingProtein kinase C eta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
actin monomer bindingProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein bindingProtein kinase C epsilon typeHomo sapiens (human)
ATP bindingProtein kinase C epsilon typeHomo sapiens (human)
enzyme activator activityProtein kinase C epsilon typeHomo sapiens (human)
enzyme bindingProtein kinase C epsilon typeHomo sapiens (human)
signaling receptor activator activityProtein kinase C epsilon typeHomo sapiens (human)
ethanol bindingProtein kinase C epsilon typeHomo sapiens (human)
metal ion bindingProtein kinase C epsilon typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C epsilon typeHomo sapiens (human)
protein serine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C theta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein bindingProtein kinase C theta typeHomo sapiens (human)
ATP bindingProtein kinase C theta typeHomo sapiens (human)
metal ion bindingProtein kinase C theta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
photoreceptor disc membraneProtein kinase C alpha typeBos taurus (cattle)
nucleusProtein kinase C alpha typeBos taurus (cattle)
cytoplasmProtein kinase C alpha typeBos taurus (cattle)
cytosolProtein kinase C alpha typeBos taurus (cattle)
plasma membraneProtein kinase C alpha typeBos taurus (cattle)
mitochondrial membraneProtein kinase C alpha typeBos taurus (cattle)
perinuclear region of cytoplasmProtein kinase C alpha typeBos taurus (cattle)
nucleusProtein kinase C gamma typeHomo sapiens (human)
cytosolProtein kinase C gamma typeHomo sapiens (human)
plasma membraneProtein kinase C gamma typeHomo sapiens (human)
cell-cell junctionProtein kinase C gamma typeHomo sapiens (human)
postsynaptic densityProtein kinase C gamma typeHomo sapiens (human)
dendriteProtein kinase C gamma typeHomo sapiens (human)
calyx of HeldProtein kinase C gamma typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C gamma typeHomo sapiens (human)
synaptic membraneProtein kinase C gamma typeHomo sapiens (human)
presynaptic cytosolProtein kinase C gamma typeHomo sapiens (human)
postsynaptic cytosolProtein kinase C gamma typeHomo sapiens (human)
nucleusProtein kinase C beta typeHomo sapiens (human)
nucleoplasmProtein kinase C beta typeHomo sapiens (human)
cytoplasmProtein kinase C beta typeHomo sapiens (human)
centrosomeProtein kinase C beta typeHomo sapiens (human)
cytosolProtein kinase C beta typeHomo sapiens (human)
plasma membraneProtein kinase C beta typeHomo sapiens (human)
brush border membraneProtein kinase C beta typeHomo sapiens (human)
calyx of HeldProtein kinase C beta typeHomo sapiens (human)
extracellular exosomeProtein kinase C beta typeHomo sapiens (human)
presynaptic cytosolProtein kinase C beta typeHomo sapiens (human)
spectrinProtein kinase C beta typeHomo sapiens (human)
cytoplasmProto-oncogene vavHomo sapiens (human)
cytosolProto-oncogene vavHomo sapiens (human)
plasma membraneProto-oncogene vavHomo sapiens (human)
cell-cell junctionProto-oncogene vavHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C eta typeHomo sapiens (human)
cytosolProtein kinase C eta typeHomo sapiens (human)
plasma membraneProtein kinase C eta typeHomo sapiens (human)
cell-cell junctionProtein kinase C eta typeHomo sapiens (human)
extracellular exosomeProtein kinase C eta typeHomo sapiens (human)
Golgi apparatusProtein kinase C epsilon typeHomo sapiens (human)
nucleusProtein kinase C epsilon typeHomo sapiens (human)
cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
mitochondrionProtein kinase C epsilon typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C epsilon typeHomo sapiens (human)
cytosolProtein kinase C epsilon typeHomo sapiens (human)
plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
intracellular membrane-bounded organelleProtein kinase C epsilon typeHomo sapiens (human)
intermediate filament cytoskeletonProtein kinase C epsilon typeHomo sapiens (human)
synapseProtein kinase C epsilon typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
cell peripheryProtein kinase C epsilon typeHomo sapiens (human)
immunological synapseProtein kinase C theta typeHomo sapiens (human)
cytosolProtein kinase C theta typeHomo sapiens (human)
plasma membraneProtein kinase C theta typeHomo sapiens (human)
aggresomeProtein kinase C theta typeHomo sapiens (human)
centriolar satelliteProtein kinase C theta typeHomo sapiens (human)
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (156)

Assay IDTitleYearJournalArticle
AID165299Relative inhibition of mutant and wild-type protein kinase C delta1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID163375Binding affinity for protein kinase C Beta-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID163373Binding affinity for protein kinase C Beta-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID517265Inhibition of [3H]PDBu binding to PKC delta C1A peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID164028Binding affinity for Protein kinase C gamma C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID164821Inhibition of [3H]-PDBu binding to PKC delta mutant Leu 24-Gly (No binding)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID164823Inhibition of [3H]PDBu binding to PKC delta mutant Pro 11-Gly1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID163159Relative binding affinity for Protein kinase C alpha1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C.
AID163676Displacement of [3H]PDBu from protein kinase C delta C1b domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID81992Compound was tested in vitro for percent EBV0EA-inducing activity in HL-60 cells. Activity is expressed as % of EA-positive cells at concentration 10e-6 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID163172Binding affinity for Protein kinase C alpha C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID163852Binding affinity for protein kinase C epsilon-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID163875Displacement of 3[H]PDBu from Protein kinase C eta C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID1138942Binding affinity to PKC-delta C1B domain (unknown origin)2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID155891Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (L24G) (Not determined)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID1189627Selectivity index, ratio of Kd for recombinant PKCalpha (unknown origin) in presence of 100 ug/ml 100% phosphatidylserine to Kd for recombinant PKCepsilon (unknown origin) in presence of 100 ug/ml 100% phosphatidylserine2015European journal of medicinal chemistry, Jan-27, Volume: 90Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).
AID1152284Binding affinity to recombinant human GFP-tagged PKC-delta expressed in human LNCAP cells assessed as induction of protein translocation from plasma membrane to internal membrane at 1000 nM after 2 to 10 mins by confocal microscopic analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.
AID163368Displacement of [3H]PDBu from protein kinase C beta C1b domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID1138946Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain P11R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID1231850Antiviral activity against HIV2 ROD infected in MT4 cells assessed as cell viability after 5 days by MTT assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID164188Binding affinity for protein kinase C Theta-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID163841Displacement of 3[H]PDBu from Protein kinase C epsilon C1a domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID232113Ratio of binding affinity to PKC delta C1b domain wild type versus mutant Q27G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID164150Activation of PKC-alpha-dependent peptide phosphorylation2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C?
AID338163Displacement of [3H]PDBU from phorbol ester site of PKC1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID608022Binding affinity to PKCalpha-C1A domain peptide using [3H]-labeled compound2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID1152282Binding affinity to recombinant human YFP-tagged PKC-epsilon expressed in human LNCAP cells assessed as induction of protein translocation from plasma membrane to internal membrane at 1000 nM after 2 to 10 mins by confocal microscopic analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.
AID163182Displacement of 3[H]PDBu from Protein kinase C alpha C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID164030Displacement of 3[H]PDBu from Protein kinase C gamma C1a domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID164181Binding affinity for Protein kinase C theta C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID164039Displacement of 3[H]PDBu from Protein kinase C gamma C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID608025Binding affinity to PKCdelta-C1B domain peptide using [3H]-labeled compound2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID608026Binding affinity to PKCepsilon-C1B domain peptide using [3H]-labeled compound2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1231848Antiviral activity against HIV1 3B infected in MT4 cells assessed as cell viability after 5 days by MTT assay2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID608023Binding affinity to PKCbeta-C1A domain peptide using [3H]-labeled compound2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID232118Ratio of binding affinity to PKC delta C1b domain wild type versus mutant W22G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID164184Binding affinity for Protein kinase C theta C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID1138957Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain N7R/L20R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID1189631Selectivity index, ratio of Kd for recombinant PKCalpha (unknown origin) in presence of nuclear membrane mimetic lipid mixture to Kd for recombinant PKCepsilon (unknown origin) in presence of nuclear membrane mimetic lipid mixture2015European journal of medicinal chemistry, Jan-27, Volume: 90Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).
AID1231846Antiviral activity against chikungunya virus Indian ocean strain 899 infected in Vero cells assessed as virus-induced cytopathic effect after 6 to 7 days2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1152286Binding affinity to recombinant human GFP-tagged RasGRP3 expressed in human LNCAP cells assessed as induction of protein translocation from plasma membrane to internal membrane at 1000 nM after 2 to 10 mins by confocal microscopic analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.
AID1138951Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain N7R/S10R/L20R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID155888Displacement of [3H]PDBu from protein kinase C delta C1b domain (Wild type)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID81991Compound was tested in vitro for its ability to induce superoxide generation in HL-60 cells at concentration 10e-9 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID163680Displacement of 3[H]PDBu from Protein kinase C delta C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID1138943Displacement of [20-3H]PDBu from GST-tagged full-length mouse PKC-delta C1B domain expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID164035Displacement of [3H]-PDBu from protein kinase C gamma C1b domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID1138955Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain L20R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID163871Displacement of 3[H]PDBu from Protein kinase C eta C1a domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID232109Ratio of binding affinity to PKC delta C1b domain wild type versus mutant L20G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID1152280Binding affinity to recombinant human GFP-tagged PKC-alpha expressed in CHOK1 cells assessed as induction of protein translocation from plasma membrane to internal membrane at 1000 nM after 5 to 15 mins by confocal microscopic analysis2014Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12
Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.
AID163178Displacement of [3H]PDBu from Protein kinase C alpha C1b domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID517266Inhibition of [3H]PDBu binding to PKC delta C1B peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID517268Inhibition of [3H]PDBu binding to PKCeta C1B peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID164040Binding affinity for protein kinase C gamma-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID163675Binding affinity for Protein kinase C delta C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID261780Activation of alpha secretase assessed by sAPPalpha secretion in W4 cells relative to control2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Branched diacylglycerol-lactones as potent protein kinase C ligands and alpha-secretase activators.
AID232112Ratio of binding affinity to PKC delta C1b domain wild type versus mutant P11G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID338200Displacement of [3H]PDBU from phorbol ester site of PKC assessed as specific binding relative to total binding1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID155885Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (T12G)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID353524Activation of mouse wild type TRPV4 expressed in HEK293 cells assessed as increase in intracellular calcium concentration2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: a structure-activity study.
AID155884Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (Q27V)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID164185Displacement of 3[H]PDBu from Protein kinase C theta C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID155893Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (Q27Q) (Not determined)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID517263Inhibition of [3H]PDBu binding to PKC beta C1A peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID1189624Displacement of [20-3H] phorbol 12, 13-dibutylate from recombinant PKCepsilon (unknown origin) in presence of 100 ug/ml 100% phosphatidylserine2015European journal of medicinal chemistry, Jan-27, Volume: 90Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).
AID163372Displacement of 3[H]PDBu from Protein kinase C beta C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID292151Displacement of [3H]PDBu from mouse PKCdelta C1b Q27E mutant expressed in Escherichia coli2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of PKC delta.
AID1138948Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain N7R/P11R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID81988Compound was tested in vitro for its ability to induce superoxide generation in HL-60 cells at concentration 10e-6 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID163173Displacement of 3[H]PDBu from Protein kinase C alpha C1a domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID232114Ratio of binding affinity to PKC delta C1b domain wild type versus mutant Q27G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID1189629Displacement of [20-3H] phorbol 12, 13-dibutylate from recombinant PKCepsilon (unknown origin) in presence of nuclear membrane mimetic lipid mixture2015European journal of medicinal chemistry, Jan-27, Volume: 90Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).
AID81990Compound was tested in vitro for its ability to induce superoxide generation in HL-60 cells at concentration 10e-8 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID163844Binding affinity for Protein kinase C epsilon C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID164034Binding affinity for Protein kinase C gamma C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID163840Binding affinity for Protein kinase C epsilon C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID517264Inhibition of [3H]PDBu binding to PKC gamma C1A peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID163849Displacement of 3[H]PDBu from Protein kinase C epsilon C1b domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID44170Tested for inhibition of EGF(epidermal growth factor) to C3H10T1/2 cells.2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C?
AID1231851Selectivity index, CC50 for african green monkey Vero cells to EC50 for HIV2 ROD2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID164820Inhibition of [3H]PDBu binding to PKC delta mutant Leu 20-Gly1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID163531Displacement of [3H]PDBu from protein kinase C delta C1a domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID1138949Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain N7R/L20R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID517267Inhibition of [3H]PDBu binding to PKCepsilon C1B peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID163364Displacement of 3[H]PDBu from Protein kinase C beta C1a domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID1138959Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain N7R/S10R/L20R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID155882Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (L20G)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID292150Displacement of [3H]PDBu from mouse wild type C1b domain of PKCdelta expressed in Escherichia coli2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of PKC delta.
AID164824Inhibition of [3H]PDBu binding to PKC delta wild type1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID608027Binding affinity to PKCeta-C1B domain peptide using [3H]-labeled compound2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID163530Binding affinity for Protein kinase C delta C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID155892Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (Q27G) (Not determined)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID163021Dissociation constant for Protein kinase C alpha1996Journal of medicinal chemistry, Jun-21, Volume: 39, Issue:13
Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C.
AID155886Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (T8G)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID163850Binding affinity for protein kinase C epsilon-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID1138952Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain N7R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID164817Inhibition of [3H]PDBu binding to PKC delta mutant Gln 27-Gly (No binding)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID163367Binding affinity for Protein kinase C beta C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID163183Binding affinity for protein kinase C Alpha-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID164170Binding affinity for protein kinase C eta-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID81993Compound was tested in vitro for percent EBV0EA-inducing activity in HL-60 cells. Activity is expressed as % of EA-positive cells at concentration 10e-7 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID164151Binding Affinity against protein kinase C alpha2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
Conformationally constrained analogues of diacylglycerol (DAG). 16. How much structural complexity is necessary for recognition and high binding affinity to protein kinase C?
AID164964Binding affinity (Ki) towards Protein kinase C1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Protein kinase C. Modeling of the binding site and prediction of binding constants.
AID163363Binding affinity for Protein kinase C beta C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID292153Binding affinity to mouse PKC delta C1a Q27E mutant expressed in Escherichia coli2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of PKC delta.
AID155873Ability to displace bound [20-3H]-PDBU from a recombinant single isozyme (PKCalpha) in the presence of phosphatidylserine2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
An optimized protein kinase C activating diacylglycerol combining high binding affinity (Ki) with reduced lipophilicity (log P).
AID1138954Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain P11R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID1138947Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain L20R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID163532Displacement of 3[H]PDBu from Protein kinase C delta C1a domain2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID155890Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (L21G) (Not determined)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID1138945Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain S10R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID517262Inhibition of [3H]PDBu binding to PKC alpha C1A peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID164191Binding affinity for protein kinase C Theta-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID163873Binding affinity for Protein kinase C eta C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID1231847Selectivity index, CC50 for african green monkey Vero cells to EC50 for chikungunya virus Indian ocean strain 8992015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID1231849Selectivity index, CC50 for african green monkey Vero cells to EC50 for HIV1 3B2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication.
AID164168Binding affinity for protein kinase C eta-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID292154Binding affinity to mouse wild-type PKCdelta C1a expressed in Escherichia coli2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of PKC delta.
AID81989Compound was tested in vitro for its ability to induce superoxide generation in HL-60 cells at concentration 10e-7 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID155883Displacement of [3H]-PDBu from protein kinase C delta C1b domain mutant (P11G)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID163185Binding affinity for protein kinase C Alpha-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID232110Ratio of binding affinity to PKC delta C1b domain wild type versus mutant L21G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID1189628Displacement of [20-3H] phorbol 12, 13-dibutylate from recombinant PKCalpha (unknown origin) in presence of nuclear membrane mimetic lipid mixture2015European journal of medicinal chemistry, Jan-27, Volume: 90Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).
AID232111Ratio of binding affinity to PKC delta C1b domain wild type versus mutant L24G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID164367Displacement of [3H]PDBu from protein kinase C theta-C1B domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID163683Binding affinity for protein kinase C Delta-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID163177Binding affinity for Protein kinase C alpha C1b domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID164048Displacement of [3H]PDBu from protein kinase C eta C1b domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID232116Ratio of binding affinity to PKC delta C1b domain wild type versus mutant T12G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID81995Compound was tested in vitro for percent EBV0EA-inducing activity in HL-60 cells. Activity is expressed as % of EA-positive cells at concentration 10e-9 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID608024Binding affinity to PKCgamma-C1A domain peptide using [3H]-labeled compound2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID1138958Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain N7R/S10R/P11R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID1138944Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain N7R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID292152Ratio of Ki for mouse wild type C1b domain of PKCdelta to Ki for mouse PKCdelta C1b Q27E mutant2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of PKC delta.
AID1138941Binding affinity to VAV1 C1 domain (unknown origin)2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID164819Inhibition of [3H]-PDBu binding to PKC delta mutant Gln 27-Val1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivit
AID1138956Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain N7R/P11R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID232115Ratio of binding affinity to PKC delta C1b domain wild type versus mutant Q27V2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID164042Binding affinity for protein kinase C gamma-C1B domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID155887Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (W22G)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID163845Displacement of [3H]PDBu from protein kinase C epsilon C1b domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
AID155881Displacement of [3H]PDBu from protein kinase C delta C1b domain mutant (F13G)2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID81994Compound was tested in vitro for percent EBV0EA-inducing activity in HL-60 cells. Activity is expressed as % of EA-positive cells at concentration 10e-8 M2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The C4 hydroxyl group of phorbol esters is not necessary for protein kinase C binding.
AID232108Ratio of binding affinity to PKC delta C1b domain wild type versus mutant F13G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID27592Partition coefficient (logP)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
An optimized protein kinase C activating diacylglycerol combining high binding affinity (Ki) with reduced lipophilicity (log P).
AID1189623Displacement of [20-3H] phorbol 12, 13-dibutylate from recombinant PKCalpha (unknown origin) in presence of 100 ug/ml 100% phosphatidylserine2015European journal of medicinal chemistry, Jan-27, Volume: 90Design and synthesis of protein kinase C epsilon selective diacylglycerol lactones (DAG-lactones).
AID1138950Displacement of [20-3H]PDBu from GST-tagged mouse PKC-delta C1B domain N7R/S10R/P11R mutant expressed in Escherichia coli after 2 to 30 mins by polyethylene glycol precipitation assay in presence of phosphatidylserine2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID232117Ratio of binding affinity to PKC delta C1b domain wild type versus mutant T8G2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
AID1138953Selectivity ratio of Ki for GST-tagged mouse PKC-delta C1B domain S10R mutant to Kd for GST-tagged full-length mouse PKC-delta C1B domain2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.
AID517269Inhibition of [3H]PDBu binding to PKCtheta C1B peptide2010Bioorganic & medicinal chemistry letters, Oct-15, Volume: 20, Issue:20
Role of the phenolic hydroxyl group in the biological activities of simplified analogue of aplysiatoxin with antiproliferative activity.
AID163870Binding affinity for Protein kinase C eta C1a domain2000Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18
Synthesis and PKC isozyme surrogate binding of indothiolactam-V, a new thioamide analogue of tumor promoting indolactam-V.
AID163681Binding affinity for protein kinase C Delta-C1A domain2003Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18
Synthesis and binding selectivity of 7- and 15-decylbenzolactone-V8 for the C1 domains of protein kinase C isozymes.
AID164029Displacement of [3H]PDBu from protein kinase C gamma C1a domain1999Bioorganic & medicinal chemistry letters, Jun-21, Volume: 9, Issue:12
Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,751)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990682 (24.79)18.7374
1990's1532 (55.69)18.2507
2000's446 (16.21)29.6817
2010's89 (3.24)24.3611
2020's2 (0.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.05 (24.57)
Research Supply Index7.94 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.04%)5.53%
Reviews15 (0.54%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2,787 (99.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]